HPQ Silicon 2025 Marked by Strategic Focus, Technical Validation, and a Clear Path Toward Commercialization

Executive Summary

• HPQ Silicon announced significant milestones in 2025 for its two primary commercial platforms: the Fumed Silica Reactor (FSR) and silicon‑based anode materials (GEN3), moving from pilot validation toward industrial scale‑up.
• The company secured up to C$3 million of Canadian government funding to build a continuous production system for silicon‑based anode material with an initial 50 t/yr capacity.
• HPQ concluded its Quartz Reduction Reactor (QRR) program to reallocate capital toward higher‑impact commercialization projects, reinforcing a disciplined focus on revenue‑generating technologies.

Key Details

• Fumed Silica Reactor (FSR) – Partnered with PyroGenesis via HPQ Silica Polvere Inc.; achieved pilot‑scale production, independent confirmation of morphology matching commercial silica, and BET surface‑area results meeting commercial specifications; progressing toward semi‑continuous operation.
• Silicon‑Based Anode Materials (GEN3) – Validated in 18650 lab cells with >1,000 cycle capacity retention, outperforming graphite anodes by ≥30%; scaled to commercially sized 18650 (4 Ah) and 21700 (6 Ah) cells; launched HPQ ENDURA+ battery platform and completed required certifications for commercial distribution.
• Government Funding – Received up to C$3 million from Canada’s Energy Innovation Program (Battery Industry Acceleration) to fund capital expenditures for a first continuous production line (50 t/yr) of silicon‑based anode material.
• Hydrogen & Waste‑to‑Energy Initiatives – Continued development of Novacium’s METAGENE™ hydrogen platform and waste‑to‑energy process under exclusive North American license; equity stake in Novacium increased to 28.4 %; projects remain at early commercialization stages with 2026 slated for market visibility.
• Strategic Realignment – Formal termination of the Quartz Reduction Reactor (QRR) silicon metal program, reallocating resources to higher‑potential commercial pathways.
• Equity & Partnership Adjustments – Increased equity interest in Novacium SAS; amended exclusive licensing agreement to clarify scope, duration, and key terms for North American commercialization rights.

Notable Quotes

“2025 was the year in which HPQ moved from broad technology development to a focused commercial intent… From independently validated GEN3 anode performance to commercial‑format cell manufacturing, certification, and now government‑supported scale‑up, we have methodically removed the key barriers between materials innovation and commercial production.” – Bernard Tourillon, Chairman, President & CEO

“The QRR was, and remains, an interesting technology… however, as a development‑stage company, we must continuously assess where our capital can be deployed most effectively.” – Bernard Tourillon, Chairman, President & CEO